Malignant pleural mesothelioma: newer aspects of carcinogenesis, molecular genetics, and prospects for future therapies.
Malignant pleural mesothelioma (MPM) is an asbestos-related disease which, although rare, is having a major social impact, and is, for the majority of cases, an incurable illness. There has been a surge of information regarding data on mesothelial transformation, mesothelioma molecular genetics and somatic gene therapy for this disease. This report summarizes the most recent investigations attempting to characterize the behaviour, on a cellular and molecular level, of MPM, with an emphasis on data from investigations performed at the National Cancer Institute with our collaborators.
Thoracic Oncology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
J S
JS
Donington
D J
DJ
Mew
H I
HI
Pass
D001195:Asbestosis / Q000150:complications; D001483:Base Sequence; D002869:Chromosome Aberrations / Q000209:etiology; D025063:Chromosome Disorders; D016207:Cytokines / Q000378:metabolism; D004249:DNA Damage; D016147:Genes, Tumor Suppressor; D015316:Genetic Therapy; D006801:Humans; D008654:Mesothelioma / Q000209:etiology / Q000235:genetics / Q000378:metabolism / Q000628:therapy / Q000821:virology; D008969:Molecular Sequence Data; D010997:Pleural Neoplasms / Q000209:etiology / Q000235:genetics / Q000378:metabolism / Q000628:therapy / Q000821:virology; D017382:Reactive Oxygen Species / Q000378:metabolism; D013539:Simian virus 40 / Q000235:genetics
D016207:Cytokines; D017382:Reactive Oxygen Species